Patents
Connective tissue substitutes, method of preparation and uses thereof
Patent Number: 7,335,230One of the areas in which regenerative medicine has caused the most advancement is in repair of connective tissue injuries. The current patent addresses this area. Specifically, the patent covers an object that can be implanted and used as a substitute for a connective tissue. The objected is made with a pair of bone anchors, with at least one filament connecting the bone achors at their...
Inventors: Goulet; Francine (Sainte-Foy, CA), Rancourt; Denis (Levis, CA), Cloutier; Rejean (Sillery, CA), Tremblay; Julie (Beauport, CA), Auger; Francois A. (Sillery, CA), Normand; Albert (Sainte-Foy, CA), German; Lucie (St-Augustin, CA), Lamontagne; Jean (St-Augus
Assignee: Universite de Montreal (Montreal, CA)
Date of First Priority Issue: Friday November 24th, 2000
Method for stimulating hair follicle cell proliferation
Patent Number: 7,335,641The current patent covers ways of induce proliferation of hair follicle cells through administration of a specific protein or variants of it. The protein is called "hair follicle growth factor" or "HFGF". HFGF is considered to be an allelic form of keratinocyte growth factor-2 (KGF-2) wherein HFGF has a glutamic acid residue (Glu) at position 87, whereas KGF-2 has a lysine residue (Lys) at this...
Inventors: Kim; Soogyun (Chungdam-dong, Gangnam-gu, Seoul, KR), Jang; Hyun-Jun (Youngdeungpo-du, Seoul, KR)
Assignee: None stated
Date of First Priority Issue: Thursday May 24th, 2001
Use of erythropoietin for the preventive or curative treatment of cardiac failure
Patent Number: 7,335,490The use of erythropoietin for non-hematopoietic purposes has been increasing in the last couple of years. One obvious example is the Canadian company Stem Cell Therapeutics (sss.v) which is using erythropoietin together with human chorionic gonadotropin for treatment of patients post-stroke. Other uses of erthrypoietin include direct
Assignee: Crucell Holland B.V. (Leiden, NL) Stichting Klinische Farmacologie Groningen (Groningen, NL)
Date of First Priority Issue: Wednesday January 9th, 2002
Compositions and treatments for myelosuppression by ex vivo activated immune cells
Patent Number: 7,332,158Failure/suppression of the hematopoietic can be a deadly consequence of over-aggressive administration of chemotherapeutics/radiotherapy. The global market for agents that stimulate hematopoiesis, particularly granulopoiesis is in the billions of dollars per year, as witnessed by the success of Amgen’s Neuopgen and Neulasta products. The current patent teaches a novel, and arguably more...
Inventors: Yang; Demao (Mountain View, CA)
Assignee: None Stated
Date of First Priority Issue: Wednesday May 29th, 2002
Hematopoietic stem cells treated by in vitro fucosylation and methods of use
Patent Number: 7,332,334On of the interesting methods of manipulating stem cells is to increase their ability to “go where they are suppose to”. For example, it is known that when bone marrow or cord blood hematopoietic stem cells are injected intravenously into an irradiated recipient, the cells selectively home to the bone marrow and if enough cells migrate appropriately, hematopoietic reconstitution occurs. Some...
Inventors: Xia; Lijun (Edmond, OK), McEver; Rodger P. (Oklahoma City, OK)
Assignee: Oklahoma Medical Research Foundation (Oklahoma City, OK)
Date of First Priority Issue: Friday April 18th, 2003
Methods for inducing differentiation of pluripotent cells
Patent Number: 7,332,336Mesenchymal stem cells are originally thought of as bone marrow derived, adherent cells, that have the ability to differentiate into a variety of tissues. Initial studies demonstrated that mesenchymal stem cells can differentiate into bone, cartilage, fat and muscle. These cells possess a very strong possibility for commercialization and therapeutics development since they can be administered to...
Inventors: Ochiya; Takahiro (Chuo-ku, JP), Teratani; Takumi (Matsudo, JP)
Assignee: Effector Cell Institute, Inc. (Meguro-Ku, JP)
Date of First Priority Issue: Saturday April 19th, 2003
Fish produced by nuclear transfer from cultured cells
Patent Number: 7,332,647One may notice that many of the patents in the StemCellPatents.com database direct their claims towards "mammals" here is one exception. The current patent is directed towards cloning of fish. The inventors state that nuclear transfer in fish was actually performed since the 1960s, however despite much work in the area, this is the first time that cultured cells are used as nucleus donors. This...
Inventors: Lin; Shuo (Los Angeles, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Tuesday June 11th, 2002
N-phenyl-3-pyrimidine-amine derivatives
Patent Number: 7,329,661This patent covers the treatment of a "proliferative disorder" using a family of compounds which include N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-- ylmethyl-benzamide methanesulfonate. These agents inhibit stem cell factor signalling, as well as signalling of PDGF.
Inventors: Buerger; Hans Michael (Allschwil, CH), Caravatti; Giorgio (Bottmingen, CH), Zimmerman; Juerg (Binningen, CH), Manley; Paul William (Arlesheim, CH), Breitenstein; Werner (Basel, CH), Cudd; Margaret Amelia (Munchenstein, CH)
Assignee: Novartis AG (Basel, CH)
Date of First Priority Issue: Tuesday September 11th, 2001
1 Comment
1 Comment
Buffy coat tube and float system and method
Patent Number: 7,329,534This patent covers a device that is capable of separating various cellular populations, or populations of particulate matter. Essentially, the device addresses the need for an easy to use, effective, and rapid method of collecting the "buffy coat" from a blood population, as well as cells within the buffy coat. The device purifies the cells using axial expansion of blood fluid components layered...
Inventors: Haubert; Thomas D. (Columbus, OH), Wardlaw; Stephen C. (Lyme, CT)
Assignee: Battelle Memorial Institute (Columbus, OH)
Date of First Priority Issue: Thursday October 3rd, 2002
Modulation of cell fates and activities by phthalazinediones
Patent Number: 7,326,690This patent covers a pharmaceutical agent, and numerous derivatives thereof, for manipulation of cellular and stem cell activity. The family of compounds covered are called phthalazinediones, and they have previously been described to possess various anti-inflammatory activities. The patent claims include methods of treatment for metabolic diseases and methods of decreasing metabolic...
Inventors: Henry; Mark O. (North Andover, MA), Lynn; William S. (Hillsborough, NC)
Assignee: Bach Pharma, Inc. (North Andover, MA)
Date of First Priority Issue: Wednesday October 30th, 2002